Business Combinations (Tables)

12 Months Ended

Oct. 02, 2015

The following table summarizes the purchase price allocation:



(In millions)	Fair Value
Net assumed liabilities	$	(0.1	)
Finite-lived intangible assets with a weighted average useful life of 6.1 years ⁽¹⁾	8.7
Indefinite-lived intangible assets — IPR&D	2.0
Goodwill ⁽²⁾	8.7
Net assets acquired	$	19.3


⁽¹⁾	$6.0 million was allocated to the Company’s Oncology Systems reporting unit and $2.7 million to the Company’s Security and inspection products reporting unit.


⁽²⁾	$5.9 million was allocated to the Company's Oncology Systems reporting unit and $2.8 million to the Company's Security and inspection products reporting unit.

The following table summarizes the purchase price allocation:



(In millions)	Fair Value
Net tangible assets ⁽¹⁾	$	21.7
Finite-lived intangible assets with a weighted average useful life of 5.4 years	5.8
Goodwill	8.2
Fair value of net assets	35.7
Less: Noncontrolling interests⁽²⁾	10.2
Net assets acquired	$	25.5


⁽¹⁾	Includes $13.9 million cash and cash equivalents.


⁽²⁾	Fair value was determined using the market price of the shares of MeVis as of the acquisition date.

The following table summarizes the purchase price allocation:



(In millions)	Fair Value
Finite-lived intangible assets with a weighted average useful life of 8.3 years	$	8.3
Indefinite-lived intangible assets — IPR&D	8.8
Goodwill	9.9
Net assets acquired	$	27.0

The following table summarizes the purchase price allocation:



(In millions)	Fair Value
Net tangible assets ⁽¹⁾	$	11.3
Finite-lived intangible assets with a weighted average useful life of 6.0 years	16.2
Goodwill	30.5
Net assets acquired	$	58.0


⁽¹⁾	Includes $1.9 million in cash and cash equivalents.

The following table summarizes the purchase price allocation:



(In millions)	Fair Value
Net assumed liabilities	$	(0.5	)
Finite-lived intangible assets with a weighted average useful life of 6.1 years	10.6
Goodwill	9.8
Net assets acquired	$	19.9